The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (the efficient trial)
International Journal of Cardiology, 06/08/2012Ari H et al.
In patients who underwent elective percutaneous coronary intervention (PCI) and had clopidogrel resistance, high–dose clopidogrel continuation therapy was more efficient in preventing MACCE than the standard dose. High–dose continuation therapy did not increase the risk of bleeding complication.
The study group consisted of 192 patients.
Of these, 98 participants without resistance served as the control group (Group 1) and received 75mg/day clopidogrel for 1month.
94 patients with resistance were randomly divided into two groups: 47 patients in the standard–dose group (Group 2) received 75mg/day continuation therapy, whereas 47 patients in the high–dose group (Group 3) received 150mg/day continuation therapy for 1month.
Clopidogrel resistance was evaluated with the VerifyNow P2Y12 test.
Patients with a platelet inhibition value lower than 40% were classified as resistant.
During the 6–month follow–up for MACCE, the event–rate in Group 2 was significantly higher than both Groups 1 and 3 (Group 1 vs Group 2; p=0.019, Group 1 vs Group 3; p=0.82, Group 2 vs Group 3; p=0.045).
Total bleeding rate in all groups were similar (Group 1 vs Group 2; p=0.54, Group 1 vs Group 3; p=0.27, Group 2 vs Group 3; p=0.16).
The rate of NACE was similar in all groups (Group 1 vs Group 2; p=0.08, Group 1 vs Group 3; p=0.50, Group 2 vs Group 3; p=0.39).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.